Nicox announces topline results from Glaucoma Dolomites Phase 2 Trial
Category: #health  | By Mateen Dalal  | Date: 2019-10-07 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Nicox announces topline results from Glaucoma Dolomites Phase 2 Trial

Glaucoma is a disease that damages a patient’s optic nerve and can eventually lead to blindness if not treated on time. It is currently considered to be the third leading cause of irreversible blindness worldwide. The current treatment of Glaucoma is targeted at reducing Intraocular pressure (IOP) to slow down the progression of the disease. Today, different organizations in the world are putting their best efforts to develop new treatments to lower IOP and treat this disease effectively.

Nicox SA, a multinational ophthalmology firm, is one such firm that has reportedly announced positive topline results from its Dolomites dose-response, U.S. multicenter phase 2 clinal trial of investigational NCX 470, a novel second-generation NO (nitric oxide)-donating bimatoprost analog which is targeted towards patients who suffer from ocular hypertension or open-angle glaucoma.

Sources cite that NCX 470 showed superiority to latanoprost ophthalmic solution, while the Phase 2 trial met the primary endpoint of non-inferiority. Moreover, the results showed IOP lowering effect of NCX 470 from baseline was 7.6 to 9.8 mmHg compared to 6.3 to 8.8 mmHg for latanoprost. Every dose of NCX 470 was also well accepted by patients with no drug-related serious adverse events

Michele Garufi, Chairman and CEO of Nicox, stated that NCX 470 0.065% showed statistical superiority to latanoprost in secondary efficiency analysis. He added that if these results would confirm in phase 3 clinical trial, then NCX 470 could become the first non-combination product which statically showed better results as compared to prostaglandin analog.

Moreover, the company is planning an end-of-phase 2 meeting with the FDA in the first quarter of next year and would announce its plans regarding Phase 3 trials against a prostaglandin analog, said Garufi.

As for Dr. Donald L. Budenz, Member of Nicox Glaucoma Clinical Advisory Board & Chairman of Ophthalmology at the University of North Carolina, Chapel Hill, these positive results indicate that NCX 470 could become a key part of treatment in patients who are suffering from open-angle glaucoma or ocular hypertension.

Source Credit - https://www.nicox.com/assets/files/EN_NCX470_Phase2_Results_20191002.pdf

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

By Mateen Dalal

American chemical company DuPont de Nemours Inc. reportedly signed a definitive agreement to buy out Spectrum Plastics Group from AEA Investors, a U.S. based private equity firm. The acquisition will reinforce DuPont’s position in booming non-c...